Bluebird bio said independent analyses found that the gene therapy inserted its payload at a site not known to cause cancer. Based on the results, CEO Nick Leschly said the company has asked the FDA for permission to resume the three clinical trials that were placed on hold in February during the inquiry.
Dr. Joshua Tamayo-Sarver
Dr. Josh Tamayo-Sarver is Vice President of Innovation at Inflect Health as well as Vice President of Innovation at Vituity, where he oversees the discovery, development, and integration of technology in the healthcare space. In addition to being the VP of Innovation, Dr. Tamayo-Sarver works clinically in the Emergency Department in his local community. He holds a bachelor’s degree with honors in biochemistry from Harvard University, a medical degree from Case Western Reserve University, a 10x10 certificate in medical informatics from Oregon Health Sciences University, and is a graduate of the Harvard Program on Negotiation.
The disease is the leading cause of US cancer deaths, and the goal of the expanded screening is to find it early enough to cure it in more people at high risk because of smoking.
MedCity News
Insurers sue ‘pharma bro’ Martin Shkreli, company for alleged price gouging
Blue Cross and Blue Shield of Minnesota has filed a class-action lawsuit on behalf of itself and insurers from 30-plus states against Martin Shkreli and Vyera Pharmaceuticals. The suit alleges the defendants intentionally monopolized the market for Daraprim to raise the price of the drug by more than 4,000%.
Shares0
The suit, filed March 4, claims that Vyera Pharmaceuticals intentionally monopolized the market for Daraprim the leading treatment for toxoplasmosis, a parasitic infection that can be fatal for those with compromised immune systems.
The company monopolized the market in order to increase the price of the drug by more than 4,000%, the suit alleges.
Date Time
MD Anderson, Orionis launch Project Helios to advance new cancer medicines
The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.
Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.